M&As this week: Avista Pharma Solutions, Venn Life Sciences Holdings

26th January 2018 (Last Updated August 12th, 2019 10:39)

Ampersand Capital Partners portfolio company Avista Pharma Solutions (APS) has acquired Solid Form Solutions Limited (SFS).

Ampersand Capital Partners portfolio company Avista Pharma Solutions (APS) has acquired Solid Form Solutions Limited (SFS).

The target company will operate from Edinburgh, Scotland, following the acquisition.

The acquisition will strengthen APS’s solid phase chemistry services.

Based in the UK, APS is a contract development and manufacturing organisation, while SFS is also based in the UK and involved in providing solid-state chemistry and crystallisation development services.

"The acquisition will help Venn Life Sciences Holdings to reinforce its data management and clinical capabilities."

Venn Life Sciences Holdings Plc has increased its stake in Venn Life Sciences (France) SAS (VLSF) to 100% by acquiring the remaining 11.03% stake in the target company from Christian Le Bras (CLB).

CLB will continue to operate as head of interactive response technology in VLS, following the acquisition.

The acquisition will help Venn Life Sciences Holdings to reinforce its data management and clinical capabilities.

Both companies are clinical research organisations based in France.